1. Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients
- Author
-
Jian-Ming Li, Edmund K. Waller, Lauren T. Southerland, and Mohammad S. Hossain
- Subjects
Muromegalovirus ,Cellular immunity ,Recombinant Fusion Proteins ,Immunology ,Vasoactive intestinal peptide ,Graft vs Host Disease ,chemical and pharmacologic phenomena ,Adaptive Immunity ,Major histocompatibility complex ,Biochemistry ,Immunocompromised Host ,Mice ,Immune system ,immune system diseases ,Immunity ,medicine ,Animals ,Transplantation, Homologous ,Cells, Cultured ,Neurotensin ,Bone Marrow Transplantation ,Mice, Knockout ,Transplantation ,biology ,Herpesviridae Infections ,Cell Biology ,Hematology ,Viral Load ,Acquired immune system ,Survival Analysis ,Up-Regulation ,Mice, Inbred C57BL ,surgical procedures, operative ,medicine.anatomical_structure ,biology.protein ,Bone marrow ,hormones, hormone substitutes, and hormone antagonists ,CD8 ,Signal Transduction ,Vasoactive Intestinal Peptide - Abstract
Cytomegalovirus (CMV) infection following allogeneic bone marrow transplant (allo-BMT) is controlled by donor-derived cellular immunity. Vasoactive intestinal peptide (VIP) suppresses Th1 immunity. We hypothesized that blocking VIP-signaling would enhance anti-CMV immunity in murine recipients of allo-BMT. Recipients were transplanted with bone marrow (BM) and T-cells from major histocompatibility complex (MHC)-mismatched VIP-knockout (KO) or wild-type donors, and treated with 7 daily subcutaneous injections of VIPhyb (peptidic VIP-antagonist) or phosphate-buffered saline (PBS). Genetic and pharmacological blockade of VIP-signaling protected allo-BMT recipients from lethal murine CMV (mCMV) infection, improving survival without increasing graft-versus-host disease. Mice treated with VIPhyb or transplanted with VIP-KO allografts had significantly lower viral loads, increased numbers of mCMV-M45-peptide-MHC-tetramer(+) CD8(+) T-cells, with lower PD-1 expression, and enhanced primary and secondary cellular immune responses after mCMV infection than did PBS-treated mice. These results demonstrate that administration of a VIP antagonist after allo-BMT is a promising safely therapeutic approach to enhance antiviral cellular immunity.
- Published
- 2013